In this article, we will list the 5 Best Strong Buy Growth Stocks to Buy Right Now. Please visit 10 Best Strong Buy Growth Stocks to Buy Right Now if you would like to see the extended list and the methodology behind it.
5. Klaviyo, Inc. (NYSE:KVYO)
Klaviyo, Inc. (NYSE:KVYO) is one of the best strong buy growth stocks to buy right now. Morgan Stanley resumed coverage of Klaviyo, Inc. (NYSE:KVYO) with an Overweight rating on April 29 and set a price target of $34. It stated that intra-quarter data points, including both channel conversations and CIO survey indicators, pointed towards durability and “signs of cautious optimism” within application SaaS fundamentals. The firm added that it prefers companies such as Klaviyo, Inc. (NYSE:KVYO), which are seen as holding the best position to deliver meaningful estimate revisions against “undemanding valuation.”
Klaviyo, Inc. (NYSE:KVYO) also received a rating update from Jefferies on April 28. The firm maintained a Buy rating on the stock with a price target of $29, with the rating update coming ahead of the company’s planned fiscal Q1 results on May 5. The firm told investors in a research note that it believes Klaviyo, Inc. (NYSE:KVYO) has the potential to deliver on consensus growth estimates of 25%, with an upside scenario of a 5-6 percentage point growth beat. It added that web traffic trends appear healthy, and the company is re-accelerating its hiring.
Klaviyo, Inc. (NYSE:KVYO) provides a SaaS marketing platform, offering personal ecommerce marketing reinvented for online stores on Shopify, Bigcommerce, and Magento.
4. Brookfield Infrastructure Partners L.P. (NYSE:BIP)
Brookfield Infrastructure Partners L.P. (NYSE:BIP) is one of the best strong buy growth stocks to buy right now. Brookfield Infrastructure Partners L.P. (NYSE:BIP) announced financial results for fiscal Q1 2026 on April 29, reporting that it generated funds from operations (FFO) per unit of $0.90, up 10% compared to the prior year. Management attributed this growth to strong base business results, with FFO from its data and midstream segments in particular growing 46% and 12%, respectively, compared to fiscal Q1 2025. It further stated that the results in its utilities and transport segments were also “notable”, showing resilient underlying performance.
Brookfield Infrastructure Partners L.P. (NYSE:BIP) also executed on several strategic and capital allocation priorities during the quarter, including securing approximately $400 million of new investment opportunities. This includes the launch of a new equipment leasing platform with an original equipment manufacturer (OEM) and an additional project under its partnership with Bloom Energy. The company also reported that it has made “meaningful progress” across its 2026 capital recycling goal, with proceeds secured of $1 billion to date.
Brookfield Infrastructure Partners L.P. (NYSE:BIP) is an infrastructure company that manages a diversified portfolio of infrastructure assets that will generate sustainable and growing distributions over the long-term for unit holders. The company operates through the Utilities, Transport, Midstream, and Data segments.
3. Celestica Inc. (NYSE:CLS)
Celestica Inc. (NYSE:CLS) is one of the best strong buy growth stocks to buy right now. Rothschild & Co Redburn initiated coverage of Celestica Inc. (NYSE:CLS) with a Buy rating on May 1, setting a price target of $460. The firm told investors in a research note that the monetization of generative AI capex would require more intelligent large language models, and that the transmission of electrical signals down copper wires will increasingly give way to the transmission of photonic signals down optical fibers.
Rothschild & Co Redburn further stated that it believes that although the transition represents a new addressable market for optical networking companies, it is significant to remember that some of the opportunity has already been discounted by the market. The firm launched coverage of six names in the AI networking space with four Buys and two Neutrals.
Celestica Inc. (NYSE:CLS) also received a rating update from CIBC on April 29. The firm lifted the price target on the stock to $480 from $425 and maintained an Outperform rating on the shares, stating that it views the selloff as a buy-the-dip setup.
Celestica Inc. (NYSE:CLS) provides supply chain solutions to equipment manufacturers and service providers across the globe. The company’s operations are divided into the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments.
2. Comfort Systems USA, Inc. (NYSE:FIX)
Comfort Systems USA, Inc. (NYSE:FIX) is one of the best strong buy growth stocks to buy right now. UBS lifted the price target on Comfort Systems USA, Inc. (NYSE:FIX) to $1,992 from $1,680 on April 27, reaffirming a Buy rating on the shares and telling investors in a research note that the company posted another strong quarter. Comfort Systems USA, Inc. (NYSE:FIX) also received a rating update from KeyBanc on April 24, with the firm upgrading the stock to Overweight from Sector Weight and setting a $2,004 price target.
Comfort Systems USA, Inc. (NYSE:FIX) announced financial results for the quarter ended March 31, 2026, on April 23, reporting that net income for the quarter was $370.4 million, or $10.51 per diluted share, as compared to $169.3 million, or $4.75 per diluted share, for the quarter ended March 31, 2025. Revenue for fiscal Q1 2026 reached $2.87 billion, up from $1.83 billion in 2025, with operating cash inflows of $388.8 million in the current quarter compared to operating cash outflows of $88.0 million in 2025.
Comfort Systems USA, Inc. (NYSE:FIX) provides mechanical and electrical contracting services, with its operations divided into the Mechanical and Electrical Services segments.
1. Eli Lilly and Company (NYSE:LLY)
Eli Lilly and Company (NYSE:LLY) is one of the best strong buy growth stocks to buy right now. Reuters reported on May 1 that Foundayo, which is Eli Lilly and Company’s (NYSE:LLY) newly launched oral weight-loss drug, hit 5,612 prescriptions in the United States in the third week following its launch, as per analysts citing IQVIA data. It further reported that RBC Capital Markets analyst Trung Huynh was of the opinion that, on initial look, the prescription data would be negatively perceived by investors. However, Huynh added that “based on ~20,000 patients on Foundayo, as of yesterday’s earnings call, it appears there is a capture rate issue with the data”.
Previously, on April 24, Reuters reported that, according to analysts citing IQVIA data, Eli Lilly and Company’s (NYSE:LLY) Foundayo was prescribed 3,707 times in the United States in the second week following its launch earlier in the month. The pill had 1,390 prescriptions in its first week of launch. Reuters provided additional perspective in the context of Eli Lilly and Company’s (NYSE:LLY) rival Novo Nordisk’s Wegovy pill. It reported that Wegovy has been on the market since January and had 3,071 prescriptions in its first week, followed by 18,410 prescriptions in the second week.
Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.
While we acknowledge the potential of LLY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LLY and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
